Added to YB: 2025-02-18
Pitch date: 2025-02-15
NVO [bullish]
Novo Nordisk A/S
-49.61%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 77.83
Price Target
755.63 (+1827%)
Dividend
4.56%
EV/EBITDA
7.01
P/E
9.79
EV/Sales
3.73
Sector
Pharmaceuticals
Category
value
Show full summary:
Novo Nordisk: Time to Buy the dip?
NVO: Diabetes/obesity leader down 43% from peak. CagriSema Phase 3 missed 25% target (-22.7%). Zepbound outperforms Wegovy. Still 55% GLP-1 market share. 16-24% rev growth, 85% margins. Risks: Lilly threat, production bottlenecks, regulatory. DCF shows 28.72% upside. Buying opportunity?
Read full article (3 min)